BACKGROUND: The World Health Organization (WHO) recommends weight band dosing of antiretrovirals for children. Data are limited describing drug exposure/safety of lopinavir/ritonavir using WHO weight band dosing. METHODS: International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1083 was a phase II/III trial assessing the pharmacokinetics (PK) and short-term safety, tolerance and efficacy of lopinavir/ritonavir in human immunodeficiency virus-infected children 3-25 kg dosed according to WHO weight bands, with liquid solution or meltrex extrusion tablets. The main PK target was an area under the curve (AUC0-24) of 80-320 μg·h/mL. RESULTS: Of 97 enrolled participants, median age 2.5 years, 89 (91.8%) completed the protocol. Median LPV dose was 303 mg/m. The geometric mean (90% confidence limits) LPV PK AUC0-24 was 196 (177-217) μg·h/mL and Cmin was 2.47 (1.52-4.02) μg/mL. AUC0-24 was within the target range for 79% of participants. The median (Q1, Q3) difference between individual observed PK parameters and those expected if Food and Drug Administration dosing guidelines were followed was 30.7 (7.9, 54.3) for AUC0-24 and 0.56 (0, 1.27) for Cmin. Ten (10%) participants had grade 3 or 4 events deemed related to study treatment, mostly asymptomatic laboratory abnormalities. Three participants died of unrelated study treatment causes. At week 24, 57 of 79 (72%) participants reached viral suppression and the median increase in CD4% (n = 83) was 6.0 (P < 0.0001). CONCLUSIONS: WHO weight band dosing guidelines in children achieved adequate LPV plasma exposure but was higher than that expected with Food and Drug Administration dosing guidelines. Despite the higher LPV exposure, the treatment was well tolerated and the 24-week efficacy data were favorable.
BACKGROUND: The World Health Organization (WHO) recommends weight band dosing of antiretrovirals for children. Data are limited describing drug exposure/safety of lopinavir/ritonavir using WHO weight band dosing. METHODS: International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1083 was a phase II/III trial assessing the pharmacokinetics (PK) and short-term safety, tolerance and efficacy of lopinavir/ritonavir in human immunodeficiency virus-infectedchildren 3-25 kg dosed according to WHO weight bands, with liquid solution or meltrex extrusion tablets. The main PK target was an area under the curve (AUC0-24) of 80-320 μg·h/mL. RESULTS: Of 97 enrolled participants, median age 2.5 years, 89 (91.8%) completed the protocol. Median LPV dose was 303 mg/m. The geometric mean (90% confidence limits) LPV PK AUC0-24 was 196 (177-217) μg·h/mL and Cmin was 2.47 (1.52-4.02) μg/mL. AUC0-24 was within the target range for 79% of participants. The median (Q1, Q3) difference between individual observed PK parameters and those expected if Food and Drug Administration dosing guidelines were followed was 30.7 (7.9, 54.3) for AUC0-24 and 0.56 (0, 1.27) for Cmin. Ten (10%) participants had grade 3 or 4 events deemed related to study treatment, mostly asymptomatic laboratory abnormalities. Three participants died of unrelated study treatment causes. At week 24, 57 of 79 (72%) participants reached viral suppression and the median increase in CD4% (n = 83) was 6.0 (P < 0.0001). CONCLUSIONS: WHO weight band dosing guidelines in children achieved adequate LPV plasma exposure but was higher than that expected with Food and Drug Administration dosing guidelines. Despite the higher LPV exposure, the treatment was well tolerated and the 24-week efficacy data were favorable.
Authors: Tim R Cressey; Saik Urien; Edmund V Capparelli; Brookie M Best; Sudanee Buranabanjasatean; Aram Limtrakul; Boonsong Rawangban; Prapan Sabsanong; Jean-Marc Treluyer; Gonzague Jourdain; Alice Stek; Marc Lallemant; Mark Mirochnick Journal: J Antimicrob Chemother Date: 2014-09-25 Impact factor: 5.790
Authors: Alice M Stek; Mark Mirochnick; Edmund Capparelli; Brookie M Best; Chengcheng Hu; Sandra K Burchett; Carol Elgie; Diane T Holland; Elizabeth Smith; Ruth Tuomala; Amanda Cotter; Jennifer S Read Journal: AIDS Date: 2006-10-03 Impact factor: 4.177
Authors: Ellen G Chadwick; Ram Yogev; Carmelita G Alvero; Michael D Hughes; Rohan Hazra; Jorge A Pinto; Brian L Robbins; Barbara E Heckman; Paul E Palumbo; Edmund V Capparelli Journal: AIDS Date: 2011-03-13 Impact factor: 4.177
Authors: Xavier Sáez-Llorens; Avyi Violari; Carl O Deetz; Richard A Rode; Perry Gomez; Edward Handelsman; Stephen Pelton; Octavio Ramilo; Pedro Cahn; Ellen Chadwick; Upton Allen; Stephen Arpadi; Maria Mercedes Castrejón; Renee S Heuser; Dale J Kempf; Richard J Bertz; Ann F Hsu; Barry Bernstein; Cheryl L Renz; Eugene Sun Journal: Pediatr Infect Dis J Date: 2003-03 Impact factor: 2.129
Authors: Alessandro Schipani; Deirdre Egan; Laura Dickinson; Gerry Davies; Marta Boffito; Mike Youle; Saye H Khoo; David J Back; Andrew Owen Journal: Antivir Ther Date: 2012-04-04
Authors: Jincheng Yang; Mina Nikanjam; Brookie M Best; Jorge Pinto; Ellen G Chadwick; Eric S Daar; Peter L Havens; Natella Rakhmanina; Edmund V Capparelli Journal: J Clin Pharmacol Date: 2018-09-25 Impact factor: 3.126